路透社11月11日 - 安进公司(AMGN.O)周三表示,在一项针对自身免疫性疾病——舍格伦综合征患者的晚期临床研究中,其试验性药物显示出能持续降低疾病活动度。
路透社11月11日 - 安进公司(AMGN.O)周三表示,在一项针对自身免疫性疾病——舍格伦综合征患者的晚期临床研究中,其试验性药物显示出能持续降低疾病活动度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.